0 Items
Select Page

Campylobacter

Campylobacter is the most common cause of food poisoning in both the UK and United States, with the great majority of cases occurring from infected poultry.

Our Campylobacter product range includes monoclonal antibodies for both for research applications and immunoassay development.

Campylobacter Background

The bacterial genus Campylobacter are non-spore forming, curved, gram-negative bacteria of the family Campylobacteriacae. Over twenty-five species of Campylobacter have been identified but approximately 90% of human disease is caused by Campylobacter jejuni. Infectious disease caused by pathogenic Campylobacter species is referred to as Campylobacteriosis. Other species of Campylobacter causing Campylobacteriosis include C. coli, C. lari and C. upsaliensis but cases are less frequently reported.

Birds, including poultry, are major reservoirs of C. jejuni, where the bacteria survive in the intestines and crop of healthy birds. Most reported outbreaks of Campylobacteriosis have been associated with the consumption of undercooked poultry or poultry products. Symptoms of infection generally include fever, abdominal cramps, watery or haemorrhagic diarrhoea and weight loss. Although the disease is self-limiting, complications may develop in some cases after infection, which include irritable bowel syndrome, Guillain Barre syndrome and other autoimmune neuropathies (CDC).

Campylobacter Antibodies

Our anti-Campylobacter jejuni monoclonal antibodies are specific for the detection of Campylobacter jejuni species and can be used as a pair in the development of immunoassays.

Our antibodies do not cross react with Helicobacter pylori, Escherichia coli, Salmonella enteriditis, Salmonella paratyphi, Salmonella typhi, Salmonella typhimurium, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Yersinia enterocolitica, Listeria monocytogenes or Staphylococcus aureus.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

From Outbreak to Epidemic: A Short History of The Ebola Virus

In the first of a two-part series, we discuss the history of the Ebola virus up to the ongoing outbreak in the Democratic Republic of Congo, and why this disease has been so challenging to fight. The 2014/15 epidemic In the summer of 2014, the world watched as the...

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

11 + 10 =

Live Customer Feedback

Join our mailing list

* indicates required